Testosterone replacement therapy (TRT) was intended to help men manage age-related hormonal decline, but hundreds of patients discovered these treatments carried a serious hidden risk: significantly increased chances of heart attack and stroke. A multidistrict litigation (MDL) involving thousands of men who suffered cardiovascular events while using testosterone products like AndroGel, Testim, and Axiron has resulted in hundreds of millions of dollars in settlements and verdicts, exposing how major pharmaceutical manufacturers failed to adequately warn patients about these dangerous complications. The litigation centered on a fundamental disconnect between how these drugs were marketed and what the science actually showed.
Men using testosterone replacement therapy have a 2-3 fold increase in risk for blood clots, with particularly vulnerable patients—men 65 years and older—facing twice the risk of heart attack within the first three months of use. Despite accumulating evidence of these risks, manufacturers continued promoting testosterone therapy, leading the FDA to intervene in 2014 with initial warnings, escalated by a mandatory safety announcement in March 2015 requiring labels about cardiovascular dangers. Between 2017 and 2018, the major pharmaceutical companies involved—AbbVie, Endo Pharmaceuticals, Eli Lilly, GlaxoSmithKline, and Auxilium Pharmaceuticals—reached major settlements worth over $290 million in combined verdicts and negotiated payouts. These cases resolved what became one of the largest drug liability litigations in recent pharmaceutical history, with the federal MDL closing by March 2025 after over a decade of legal battles.
Table of Contents
- What Was the Testosterone Replacement Therapy Heart Attack Litigation?
- The Cardiovascular Risks Behind the Litigation
- The Litigation Structure and Timeline
- Major Settlements and Financial Resolutions
- Trial Outcomes and Product-Specific Claims
- FDA Regulatory Actions and Warning Evolution
- Litigation Legacy and Current Status
- Conclusion
What Was the Testosterone Replacement Therapy Heart Attack Litigation?
The testosterone replacement therapy litigation emerged from growing evidence that testosterone products, while potentially beneficial for managing specific hormonal conditions, posed severe cardiovascular risks when used inappropriately. In June 2014, the U.S. Judicial Panel on Multidistrict Litigation created MDL-2545 in the U.S. District Court for the Northern District of Illinois under Judge Matthew F. Kennelly to consolidate hundreds of individual lawsuits into a coordinated proceeding.
This consolidated approach allowed thousands of plaintiffs to pursue claims more efficiently than through entirely separate court cases. The core of these lawsuits involved a critical allegation: manufacturers knew or should have known about cardiovascular risks but failed to adequately warn prescribing physicians and patients. A man in his mid-60s who suffered a heart attack after starting AndroGel exemplified the pattern seen across many cases—patients prescribed testosterone therapy without being informed that men in his age group faced doubled risk of cardiovascular events in the first ninety days of treatment. The litigation wasn’t simply about whether testosterone products caused harm, but whether companies deliberately obscured known risks from their marketing and warnings. By March 2025, the MDL had been closed with no federal cases remaining in Illinois federal court, marking the formal end of what had been a nearly eleven-year litigation process. However, the settlements and verdicts reached during this period established important precedent about pharmaceutical liability and the consequences of inadequate cardiovascular risk warnings.
The Cardiovascular Risks Behind the Litigation
Medical evidence presented in these cases revealed alarming cardiovascular complications associated with testosterone replacement therapy. Men using testosterone products experienced a 2-3 fold increase in their risk for blood clots, which can dislodge and travel to the lungs (pulmonary embolism), brain (stroke), or heart (heart attack). For older men—those 65 years and older—the risks were even more pronounced, with studies showing twice the risk of heart attack within the first three months of initiating therapy. The mechanism behind these risks involves testosterone’s effects on blood clotting factors and vascular function. Higher testosterone levels can increase the body’s tendency to form clots, and in patients with existing cardiovascular vulnerabilities—often undiagnosed in older men—this increased clotting tendency becomes particularly dangerous.
A limitation of early testosterone replacement therapy protocols was insufficient pre-treatment cardiovascular screening. Many physicians prescribed testosterone without first establishing baseline cardiac health or identifying patients at highest risk, a practice that made dangerous outcomes more likely. The FDA’s March 3, 2015 safety announcement represented a critical turning point, mandating that manufacturers warn about increased risk of heart attacks and strokes. However, by that date, thousands of men had already been exposed to these risks without informed consent. The announcement also specified that testosterone therapy products are not approved for treating low testosterone due to aging alone—a crucial distinction that many marketers and prescribers had blurred, treating age-related hormonal decline as if it were a medical condition requiring testosterone intervention.
The Litigation Structure and Timeline
MDL-2545 consolidated claims from multiple sources: patients who had purchased testosterone products directly, those prescribed testosterone through medical professionals, and individuals who developed cardiovascular complications while using these therapies. Judge Matthew F. Kennelly presided over the complex litigation that involved coordinating thousands of individual claims against several major pharmaceutical manufacturers simultaneously. The timeline of the litigation spanned from the MDL’s creation in June 2014 through its closure in March 2025, with the most significant legal activity occurring between 2017 and 2018.
During this 18-month period, major settlements were announced almost quarterly, suggesting that manufacturers faced mounting litigation risks and costs that made settlement more economically prudent than continuing to trial. The various companies involved—AbbVie (manufacturer of AndroGel), Endo Pharmaceuticals (Testim), Eli Lilly, GlaxoSmithKline, Allergan, and Auxilium Pharmaceuticals—each negotiated separate settlement agreements with different numbers of claimants. This consolidation approach provided efficiency but also presented challenges for individual plaintiffs, as the MDL structure meant that not every case received individual jury consideration. Many claims were resolved through settlement negotiations based on damages models calculated from the few cases that did proceed to trial, creating a variation in settlement amounts based on the strength of individual claims.
Major Settlements and Financial Resolutions
The settlements reached during this litigation represented substantial financial acknowledgments of wrongdoing and harm. In June 2018, Endo Pharmaceuticals agreed to pay $200 million to settle approximately 1,300 Testim lawsuits, with roughly 900 of those cases being part of the federal MDL. This settlement demonstrated that despite not admitting liability, Endo found settlement economically preferable to litigation risk. AbbVie, the manufacturer of the most widely used testosterone product, AndroGel, faced the largest settlements. In September 2018, AbbVie announced a tentative settlement covering 4,200 lawsuits, and notably, two individual plaintiffs who had taken their AndroGel cases to trial had already received combined verdicts exceeding $290 million.
These verdicts—both favoring plaintiffs in cases involving heart attacks directly linked to AndroGel use—served as strong negotiating leverage that likely influenced AbbVie’s willingness to settle the broader cohort of claims. Other manufacturers reached settlements at different scales. In December 2017, Eli Lilly settled 400 federal lawsuits. In February 2018, Endo Pharmaceuticals, Auxilium Pharmaceuticals, and GlaxoSmithKline reached a coordinated settlement covering 1,300 federal lawsuits. The variation in settlement sizes reflected differences in the number of claims, the strength of plaintiffs’ evidence in different cases, and the different market positions of each manufacturer’s products. A downside for many plaintiffs was that settlement amounts didn’t always fully compensate for the severity of some injuries, particularly cases involving multiple complications or permanent cardiac damage requiring ongoing treatment.
Trial Outcomes and Product-Specific Claims
While the majority of testosterone replacement therapy claims resolved through settlement, a sufficient number proceeded to trial to establish patterns in how juries and judges evaluated the evidence. Of the cases that reached trial verdicts, court rulings favored defendants in 9 cases (representing 36% of trials) and plaintiffs in 3 cases (12% of trials), with the remaining trials likely resulting in mixed verdicts or mistrials. This less-than-majority plaintiff victory rate reflected the complexity of proving that a specific product directly caused a cardiovascular event in individual patients, particularly when older men often have multiple pre-existing cardiac risk factors. The affected products in this litigation included AndroGel, Axiron, Fortesta, and Testim, manufactured by AbbVie, Eli Lilly, Endo International, Auxilium Pharmaceuticals, GlaxoSmithKline, and Allergan.
Each product had different formulations, delivery methods (gels, patches, topicals), and marketing approaches, though all carried the fundamental cardiovascular risk profile. A limitation in defending these cases was that manufacturers’ own internal research data often showed evidence of cardiovascular risks that hadn’t been adequately communicated to prescribers or patients—a warning sign that juries found particularly compelling in the cases that ruled for plaintiffs. The trial outcomes emphasized that individual case circumstances matter significantly. A 58-year-old man with a prior history of hypertension who suffered a stroke after starting testosterone therapy presented a stronger causal argument than a 72-year-old with extensive pre-existing cardiac disease, even if both experienced cardiovascular events while using testosterone products.
FDA Regulatory Actions and Warning Evolution
The FDA’s regulatory response to testosterone replacement therapy safety concerns unfolded in stages, beginning with an initial warning in 2014 and becoming mandatory on March 3, 2015. The 2015 safety announcement required all testosterone therapy manufacturers to add warnings about increased risk of heart attacks and strokes to their labeling. Additionally, the FDA clarified that testosterone therapy products are not approved for treating low testosterone due to aging alone—a statement that directly contradicted how many of these products had been marketed and prescribed.
This regulatory clarification highlighted a significant gap in how testosterone therapy had been promoted. While testosterone replacement can be appropriate for men with documented hypogonadism (clinically low testosterone from specific medical conditions), manufacturers and some healthcare providers had blurred the distinction between treating a genuine medical condition and treating normal age-related hormonal decline. The FDA’s statement essentially said that using these products for the latter purpose lacked regulatory approval, making prescriptions for that indication technically off-label. Patients who had been prescribed testosterone based primarily on age and non-specific symptoms had a stronger litigation position than those with documented hormonal deficiency.
Litigation Legacy and Current Status
The closure of MDL-2545 by March 2025 marked the formal end of the federal multidistrict litigation, but the cases’ impact on pharmaceutical practice and cardiovascular risk management persists. The settlements and verdicts established precedent that manufacturers bear responsibility for adequately communicating known cardiovascular risks, and the financial consequences—totaling hundreds of millions of dollars—have influenced how pharmaceutical companies approach risk disclosure in hormone-related medications.
The testosterone replacement therapy litigation demonstrated that drug safety concerns can take years to fully litigate but ultimately result in substantial accountability. The combination of early trial victories favoring plaintiffs (the $290 million verdicts for two individual plaintiffs), regulatory pressure from the FDA, and the mounting costs of ongoing litigation created circumstances where settlement became rational business strategy for manufacturers. This case serves as a reference point for other pharmaceutical litigation involving products marketed for age-related conditions without adequate cardiovascular risk stratification.
Conclusion
The testosterone replacement therapy heart attack litigation consolidated thousands of claims from men who suffered cardiovascular events—heart attacks, strokes, and blood clots—while using testosterone products like AndroGel, Testim, and Axiron. Between June 2014 and March 2025, the MDL resulted in over $290 million in individual verdicts and hundreds of millions more in company settlements, establishing that manufacturers failed to adequately warn patients and physicians about the 2-3 fold increased risk of blood clots and doubled heart attack risk in men 65 and older during the first three months of therapy.
If you used testosterone replacement therapy and subsequently experienced a heart attack, stroke, or blood clot, you may have had grounds for a claim in this litigation. While the federal MDL has closed, understanding whether you had a viable case—based on your age at treatment initiation, pre-existing cardiovascular risk factors, the specific product used, and the timeline of your cardiovascular event—remains important for your medical records and potential claims against remaining liable parties. Consulting with a product liability attorney familiar with testosterone replacement therapy cases can clarify whether you might still pursue claims through state court actions or whether you were among the claimants already compensated through the MDL settlements.